Evogene (NASDAQ:EVGN) Now Covered by StockNews.com

StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN) in a research report report published on Monday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital lowered their price target on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, August 23rd.

Evogene Stock Performance

Shares of EVGN stock opened at $1.68 on Monday. The firm has a market cap of $9.02 million, a price-to-earnings ratio of -0.44 and a beta of 1.43. Evogene has a 52 week low of $1.66 and a 52 week high of $10.40. The firm’s 50-day simple moving average is $2.49 and its two-hundred day simple moving average is $4.59.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.94). Evogene had a negative return on equity of 72.33% and a negative net margin of 210.26%. The company had revenue of $0.91 million during the quarter.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC bought a new position in Evogene Ltd. (NASDAQ:EVGN) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.